Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?

Cristina SmolenschiElie RassyJohan PalludEdouard DezamisRazvan CopaciuFabrice ParkerGabriel GarciaNaima LezghedEmeline ColombaMohamed KhettabSami AmmariMohamed FekhiLarisa MartanovschiLina BenadhouSteven KnafoDavid GuyonBianca CheaibFrederic DhermainSarah Naomie Dumont

Published in: Journal of neurology (2023)

This study reports a clinical benefit and an acceptable toxicity profile in patients with recurrent glioblastoma treated with bevacizumab. As the panel of therapies is still very limited for these tumors, this work supports the use of bevacizumab as a therapeutic option.

Keyphrases

metastatic colorectal cancer
oxidative stress
emergency department
adverse drug
drug induced